对安东基亚尼丁对葡萄糖酶调节蛋白的抑制潜力的分子见解
Christian Kenneth1, Daru Seto Bagus Anugrah1, Jeffry Julianus2
1Biotechnology Study Program, Faculty of Biotechnology, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
PloS one
|July 19, 2023
概括
根据计算研究,pelargonidin是一种天然的安托西亚尼丁,通过有效抑制葡萄糖酶调节蛋白 (GKRP) 活性,显示出作为抗糖尿病营养药的强大潜力.
科学领域:
- 生物化学 生物化学
- 计算化学计算化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 葡萄糖酶调节蛋白 (GKRP) 在葡萄糖代谢中起着至关重要的作用.
- 抑制GKRP活性是治疗糖尿病的潜在治疗策略.
- 安东基亚尼丁是具有各种健康益处的天然化合物,包括潜在的抗糖尿病作用.
研究的目的:
- 通过计算来研究六种安东基亚尼丁的潜力,作为葡萄糖酶调节蛋白 (GKRP) 的抑制剂.
- 为了确定具有高结合亲和力与GKRP的特定安东基亚尼丁.
- 阐明基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因
主要方法:
- 密度函数理论 (DFT) 用于几何优化和量子化学属性计算.
- 盲目分子对接,以预测结合模式和亲和关系.
- 分子动力学 (MD) 模拟和MM/GBSA计算,以评估复杂的稳定性和结合的自由能量.
主要成果:
- 德尔菲尼丁,氨和佩拉戈尼丁对GKRP具有最高的结合亲和力,结合的自由能量分别为-8.7kcal/mol,8.6kcal/mol和8.6kcal/mol.
- 分子动力学模拟证实了GKRP-F1P-pelargonidin复合物的稳定性.
- 佩拉戈尼丁被证明可以保持GKRP在非活性构造中,抑制葡萄糖激素酶结合.
结论:
- 佩拉戈尼丁在被研究的安东基亚尼丁中表现出作为GKRP抑制剂最显著的潜力.
- 安西亚尼丁,特别是佩拉戈尼丁,是作为抗糖尿病营养药物开发的有希望的天然产品.
- 这项研究确定了参与GKRP抑制的关键残留物,为进一步的药物设计提供了基础.
相关概念视频
Feedback Inhibition
54.0K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
54.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
Enzyme Inhibition
78.7K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.7K
GPCRs Regulate Adenylyl Cylase Activity
5.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Dipeptidyl Peptidase 4 Inhibitors
213
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
213


